News | contract research
05-03-2012 | reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast
09-05-2011 | reMYND’s CRO receives governmental grant for a continued innovation of its offering
On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization (CRO) for the ‘Evaluation of candidate behavioral and synaptic markers in transgenic Alzheimer mouse models, to assess the feasibility of developing such early onset markers for large scale in vivo testing’, herewith recognizing the deliberated innovation efforts of the CRO.
08-09-2010 | reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model.
06-07-2010 | reMYND and Amorfix announce agreement
Press Release | Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in‐vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).
20-08-2008 | reMYND licenses highly innovative transgenic mouse models
reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven.
Visit the University of Leuven website
